Adia Nutrition Inc (ADIA)

[jrlsss]

I guess we wait until Adia uplists to OTCQB and gets some interest. It's stalled with little or no volume.

[Jaguarjacket]

Spread is Tight!!!!

[samson8]

Mark McKelvie/Razor Pitch is a paid promoter company. They are the ones that got the promo badge applied to APSI before all that mess happened. Im sure BB would remember that? He was trying to get people to buy in the .50 range and now its at .02.

[i_like_bb_stock]

we're mentioned here: https://www.abnewswire.com/pressreleases/stem-cell-innovators-4-companies-advancing-regenerative-medicine_738086.html

[Jaguarjacket]

This is just the beginning of our efforts to deliver long-term growth and stability."

[Jaguarjacket]

Share Reduction Complete! A judge has ordered the cancellation of over 25 million shares of Adia Nutrition stock, including more than 15 million restricted common shares and 10 million preferred shares.

[i_like_bb_stock]

nice news big share reduction https://www.otcmarkets.com/stock/ADIA/news/story?e&id=3194846

[AyaStocks]

2 expansion news out this week >>

Adia Med Explores International Expansion Following Global Interest in Its Innovative Umbilical Cord Blood Stem Cell Therapies
https://www.otcmarkets.com/stock/ADIA/news/Adia-Med-Explores-International-Expansion-Following-Global-Interest-in-Its-Innovative-Umbilical-Cord-Blood-Stem-Cell-The?id=471455

Adia Nutrition Inc. Opens First Satellite Location in Tinton Falls, NJ, Partnering with Keep Glowing Medical Spa and Dr. Michael Ellis
https://www.otcmarkets.com/stock/ADIA/news/Adia-Nutrition-Inc-Opens-First-Satellite-Location-in-Tinton-Falls-NJ-Partnering-with-Keep-Glowing-Medical-Spa-and-Dr-Mic?id=471696

$ADIA

[Jaguarjacket]

ADIA has Accomplished So much in Just 2 Months! It's amazing!

[Jaguarjacket]

ADIA Opening of its first satellite location in Tinton Falls, New Jersey. OUTSTANDING NEWS!

[Jaguarjacket]

Next up OTCQB Uplisting! Then Financials!

[samson8]

Anyone have a replay of the webinar? Im concerned that someone said they are still waiting on FL to open their clinic.

[konshe]

No trading volume with news? market is bear

[i_like_bb_stock]

agreed hopefully see the audit completed and otcqb

[downdraft]

Very cool news. Just a matter of time before revenues flow in earnest.

[AyaStocks]

Adia Nutrition Inc. Opens First Satellite Location in Tinton Falls, NJ, Partnering with Keep Glowing Medical Spa and Dr. Michael Ellis
Winter Park, Florida--(Newsfile Corp. - March 27, 2025) - Adia Nutrition Inc. (OTC Pink: ADIA), a leader in regenerative medicine and healthcare innovation, is excited to announce the opening of its first satellite location in Tinton Falls, New Jersey. This expansion is made possible through a strategic shared space agreement with Keep Glowing Medical Spa and renowned physician Dr. Michael Ellis, blending cutting-edge stem cell therapies with an established wellness hub.

Located within Keep Glowing Medical Spa, the new satellite site will operate under Adia Nutrition's medical division, Adia Med, offering FDA-compliant regenerative treatments such as AdiaVita (umbilical cord stem cells with 100 million viable cells and 3 trillion exosomes per unit) and AdiaLink (3.5 trillion exosomes per unit). These therapies, produced in partnership with an FDA-approved laboratory, meet Section 361 of the Public Health Service Act standards for minimal manipulation and homologous use, targeting conditions like inflammation, autoimmune disorders, and musculoskeletal issues.


Cannot view this image? Visit: https://images.newsfilecorp.com/files/10520/246027_keep_glow_website__550.jpg

https://keepglowingmedicalspa.com/

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/246027_keep_glow_website.jpg

"We're proud to collaborate with Keep Glowing Medical Spa and Dr. Michael Ellis to bring our regenerative solutions to Tinton Falls," said Larry Powalisz, CEO of Adia Nutrition Inc. "This shared space partnership taps into Keep Glowing Medical Spa's top-tier facility and Dr. Mike Ellis's exceptional expertise, letting us bring transformative care to you in a cost-effective, community-centered way. It's a seamless blend of innovation and a personal approach that puts patients first."

Dr. Michael Ellis, a respected figure in integrative medicine, will oversee clinical operations at the Tinton Falls location, ensuring patients receive personalized, high-quality care. Keep Glowing Medical Spa's established reputation for advanced aesthetic and wellness services complements Adia Med's mission, creating a seamless integration of regenerative therapies into their offerings. This partnership marks the first step in Adia Nutrition's plan to expand through similar collaborations nationwide, following the successful launch of its flagship clinic in Winter Park, Florida, in January 2025.


Cannot view this image? Visit: https://images.newsfilecorp.com/files/10520/246027_dr__michael_ellis_550.jpg

Dr. Michael Ellis

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/246027_dr__michael_ellis.jpg

The Tinton Falls satellite will provide patients with access to Adia Med's ethically sourced, lab-verified stem cell products without the need for international travel. By sharing space, Adia Nutrition reduces overhead while tapping into an existing patient base, setting a scalable model for future growth in the $15.1 billion global stem cell market.

For appointments or inquiries, contact Keep Glowing Medical Spa at 848-217-2662 or Adia Med at ceo @101Dahlias-0850. Investors and media can learn more about this milestone in Adia Nutrition's journey to redefine healthcare.

For questions, inquiries or further information, please contact Larry Powalisz at ceo @101Dahlias-0850.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.

Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

info
SOURCE: Adia Nutrition Inc.

https://www.newsfilecorp.com/release/246027/Adia-Nutrition-Inc.-Opens-First-Satellite-Location-in-Tinton-Falls-NJ-Partnering-with-Keep-Glowing-Medical-Spa-and-Dr.-Michael-Ellis

$ADIA

[i_like_bb_stock]

news https://www.otcmarkets.com/stock/ADIA/news/Adia-Nutrition-Inc-Opens-First-Satellite-Location-in-Tinton-Falls-NJ-Partnering-with-Keep-Glowing-Medical-Spa-and-Dr-Mic?id=471696

[samson8]

Wait they don't have approval for their clinic yet? Why have they been PRing that they are taking patients then?

[downdraft]

Webinar was great. Key takeaways for me was the cost for an aHSCT treatment was currently in the range of $116,000 to $150,000 depending upon insurance and other factors. Also, as expected, still waiting on the state of Florida for clinic approval and have been interacting with them. Hopefully we're just several weeks away on that. And a third thing was the big name insurance companies they've reached out to for insurance approval once the state of Florida provides clinic approval.

[jrlsss]

I watched the webinar on HSCT and it was very informative. I'm sure very few people are aware of the options. Biggest hurdle will be educating the masses beyond this platform. Hopefully, the company can obtain insurance approval. If so, the flood gates should open.

[samson8]

Probably the one who bought the Reg A at .0005

[jrlsss]

Someone continues to unload 10,000 shares at $.07 everytime the ask hits $.09.

[AyaStocks]

New tweet out today! >>

$ADIA
A quick reminder!
WEBINAR TODAY AT 6PM EST

Exciting news!
Adia Med is joining HSCT Warriors for a webinar tonight. Adia’s Board of Directors and doctors will be on the call, sharing insights about Adia’s innovative treatments. Stick around for the Q&A at the end—your…

— Adia Nutrition (@ADIA_Nutrition) March 26, 2025

[Jaguarjacket]

$ADIA A quick reminder! WEBINAR TODAY AT 6PM EST
Exciting news!
Adia Med is joining HSCT Warriors for a webinar tonight. Adia’s Board of Directors and doctors will be on the call, sharing insights about Adia’s innovative treatments. Stick around for the Q&A at the end—your chance to ask about Adia's treatments or the company.
Don’t miss it!
hsctwarriors.org/event/learn-wi…

[AyaStocks]

$ADIA = 100% BUY!

[Jaguarjacket]

Cant wait for news on Expansion in the United States as well!

[Jaguarjacket]

True, we need revenues and sales contracts! No pump though, just keeping investors up to date on ADIA business weekly. I love it! It's all coming together, takes time. Long!

[AyaStocks]

Adia Med Explores International Expansion Following Global Interest in Its Innovative Umbilical Cord Blood Stem Cell Therapies
Winter Park, Florida--(Newsfile Corp. - March 25, 2025) - Adia Nutrition (OTC Pink: ADIA), a trailblazer in advanced healthcare solutions, is excited to announce that its subsidiary, Adia Med, is actively exploring international expansion after receiving significant interest from multiple international groups. Over recent months, several organizations and healthcare entities from various countries have reached out to Adia Med, expressing enthusiasm for establishing clinics that offer its cutting-edge treatments, including Therapeutic Plasma Exchange (TPE), Hematopoietic Stem Cell Transplantation (HSCT), and notably, umbilical cord blood stem cell (UCB-SC) therapies utilizing Adia Labs' premier product, Adia Vita. In response, Adia Med has begun a comprehensive review of the legalities and regulations required to bring its pioneering care to a global stage.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/10520/243471_1.jpg

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/243471__bf477173-b44d-457c-bb35-7984f21e1815.jpg

Adia Med's leadership has taken proactive steps toward this potential expansion, consulting legal experts to evaluate the feasibility of operating clinics abroad. The company recently received a letter of opinion from its legal counsel, confirming that international expansion is permissible and providing a detailed blueprint for navigating the regulatory landscape. This legal framework outlines the steps needed to comply with international healthcare standards, setting the stage for Adia Med to extend its innovative therapies, including the highly sought-after Adia Vita, beyond the United States.

"We've been overwhelmed by the global enthusiasm for our work, particularly from groups interested in leveraging Adia Labs' Adia Vita for umbilical cord blood stem cell therapies," said Larry Powalisz, CEO of Adia Med. "Our current location is already delivering transformative treatments, and with this international outreach, we're exploring how to share our advancements, like Adia Vita, our premier stem cell product, with the world. We've already identified an appealing location outside the U.S. that we're likely to pursue, and our lawyer's guidance assures us that going international is within reach."

Adia Vita, offered by Adia Labs, has garnered attention for its unprecedented potency and purity, making it a standout in regenerative medicine. International groups have expressed keen interest in utilizing this premier UCB-SC product for therapies targeting a range of conditions, from circulatory disorders to orthopedic applications. Adia Med's expertise with apheresis machines for TPE and HSCT, combined with its leadership in UCB-SC therapies, positions it as one of only three clinic networks in the U.S. with this technology—a distinction that has fueled global curiosity.

While the expansion remains in the planning phase, Adia Med is committed to meeting this international demand by carefully assessing regulatory requirements, forging strategic partnerships, and refining its approach to ensure a smooth entry into new markets. Larry Powalisz, CEO of Adia Nutrition, shared, "We've recently pinpointed a specific location outside the US for launching our first international Adia Med," signaling a clear step toward global outreach. This move aligns with Adia Nutrition's mission to revolutionize healthcare and deliver impactful solutions worldwide, leveraging their expertise in regenerative medicine to reach new patients beyond U.S. borders.

For more information about Adia Med's current offerings, including Adia Vita, or updates on its international plans, please visit www.adiamed.com or contact [e-mail].

About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.

Website: www.adianutrition.com

Website: www.adiamed.com

Website: www.adialabs.com

Website: www.biolete.com

Website: www.cementfactory.co

Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

info
SOURCE: Adia Nutrition Inc.

https://www.newsfilecorp.com/release/243471

$ADIA

[downdraft]

Whoa! The CEO has international ambitions as well! Maybe he wants to be the world leader in stem cell therapy. The U.S. was good enough for me. People will kick themselves someday for not getting in early, IMO!

[samson8]

LMAO. How about they show us revenues on their first clinic? The pump is unreal on this one

[i_like_bb_stock]

news https://www.otcmarkets.com/stock/ADIA/news/Adia-Med-Explores-International-Expansion-Following-Global-Interest-in-Its-Innovative-Umbilical-Cord-Blood-Stem-Cell-The?id=471455

[samson8]

Its a paid promotional article. "All Cap Research" is a stock promoter.

[AyaStocks]

Nice article write-up about $ADIA over the weekend >>

Adia Med Pushes for National Stem Cell Standards, OTCQB Uplist
Raising the Standard for Stem Cell Therapy – Quality, Safety, Trust.
Adia Med, a division of ADIA Nutrition Inc. (OTC Pink: ADIA), is spearheading a major initiative to establish standardized regulations for umbilical cord stem cell use across the United States. With a focus on quality, safety, and accountability, the company is setting new industry benchmarks that mandate best practices, third-party verification, and homologous applications. These efforts aim to address inconsistencies in stem cell therapies and ensure patient confidence in the emerging field of regenerative medicine.

The Problem: Inconsistent Stem Cell Quality
One of the most pressing issues in the regenerative medicine industry is the lack of standardized quality control. Many clinics provide substandard or even non-viable—so-called "dead"—stem cells without any means for recipients to verify potency or quantity. This inconsistency has eroded trust and prevented patients from fully benefiting from groundbreaking medical advancements.

Adia Med is committed to changing this landscape. "Umbilical cord stem cells could revolutionize healthcare, but only if patients can trust what they're getting," said Larry Powalisz, CEO of Adia Nutrition. "We're crafting a movement for reliability and excellence, and we're taking it to the new head of the Department of Health and Human Services and the FDA to create a national standard that protects patients and lifts the entire industry."

A Comprehensive Standardization Framework
To ensure every patient receives live, viable stem cells, Adia Med is implementing a robust framework that prioritizes:

1. Homologous Use Standards
Guidelines will be enforced to ensure that stem cells are used in alignment with their natural functions. This approach maximizes safety and efficacy while preventing misuse.

2. Rigorous Quality Control Protocols
Strict procedures for harvesting, processing, and storing stem cells will maintain their therapeutic power. This includes comprehensive donor screening, isolation, and banking methods to uphold the highest standards of care.

3. Third-Party Verification
Every lab offering stem cell products will be required to conduct third-party verification to guarantee a minimum stem cell count and viability for each batch. This will create a transparent, reliable system ensuring patient safety and product integrity.

4. Best Practices Development
By collaborating with stem cell experts, ethicists, and healthcare practitioners, Adia Med will establish industry-wide standards that eliminate variability and improve patient outcomes.

"Doctors should be getting their stem cells from a lab that has a third-party verified, FDA-validated process that guarantees quality," stated Dr. Sher, Chief Medical Officer of Stem Cells at Adia Med. "We're pushing to make that the industry baseline with umbilical cord stem cells."

Tackling a Growing Concern
Reports of patients receiving substandard or ineffective stem cells are increasing. Many patients remain unaware that they have received dead cells until they see no results. Adia Med’s verification standards will require all providers to use only live, viable stem cells in guaranteed minimum quantities. The expected benefits include:

Enhanced Patient Safety: Reducing risks associated with poor-quality or improperly used stem cells.
Greater Treatment Consistency: Ensuring reliable results nationwide, regardless of the provider.
Stronger Industry Credibility: Establishing ethical standards to eliminate unregulated and unscrupulous practices.

Federal Collaboration and the Path Forward
To solidify its efforts, Adia Med plans to present its standards to the newly appointed head of the Department of Health and Human Services (DHHS) and the FDA. The company hopes to work closely with federal agencies to align regulatory frameworks and enforce a national standard for umbilical cord stem cell therapies.

"With the leadership of DHHS and the FDA, we can end uncertainty and deliver real benefits to patients across the country," Powalisz emphasized. "By working together, we can ensure that the potential of regenerative medicine is fully realized."

Adia Med is also calling on regulators, medical professionals, and patient advocates to participate in shaping this national framework. Interested parties can learn more and contribute by visiting www.adiamed.com.

CEO Larry Powalisz and ADIA Nutrition’s Growth Vision
Larry Powalisz, CEO of Adia Nutrition, has been at the forefront of innovation in both the supplement and medical sectors. Under his leadership, Adia Nutrition has expanded its focus beyond dietary supplements to include groundbreaking regenerative medicine solutions.

A significant goal for Powalisz and Adia Nutrition is the company's planned uplisting to the OTCQB market. This move would increase transparency, attract institutional investors, and provide greater credibility within the financial markets. "We are working diligently to meet the requirements for an OTCQB uplisting, which will allow us to reach a broader investor base and enhance shareholder value," Powalisz stated.

The planned uplisting aligns with Adia Nutrition’s long-term vision of becoming a leader in both stem cell therapies and holistic health solutions. By securing a stronger market presence, the company aims to accelerate the adoption of its innovative stem cell initiatives while expanding its reach in the healthcare industry.

Conclusion
Adia Med is leading a transformative effort to standardize umbilical cord stem cell use across the United States. With a focus on quality control, third-party verification, and federal collaboration, the company is setting a new benchmark for the regenerative medicine industry. CEO Larry Powalisz remains committed to pushing for these changes while also positioning Adia Nutrition for future growth through its planned OTCQB uplisting.

As Adia Med prepares to present its framework to DHHS and the FDA, the company stands at the forefront of an industry revolution that promises to improve patient outcomes and restore trust in stem cell therapies. Those interested in joining this movement can find further details at www.adiamed.com.
https://allcapresearch.com/penny-stocks/f/adia-med-pushes-for-national-stem-cell-standards-otcqb-uplist?blogcategory=Pennystocks

[BCNstocks]

Adia Med ($ADIA) is working towards a future where national standards govern the use of stem cell therapies. These standards aim to eliminate variability in treatment quality and establish a system of accountability and transparency.

With a focus on third-party verification, donor screening, and strict quality control measures, Adia Med is ensuring that stem cell treatments are both effective and safe for patients. The company’s efforts are expected to improve patient outcomes, restore confidence in the industry, and help push regenerative medicine toward mainstream acceptance.

By aligning with federal regulatory agencies like the FDA and DHHS, Adia Med hopes to ensure that stem cell therapies are subject to the same rigorous oversight as other medical treatments, leading to a stronger, more reliable industry overall.

Adia Med Pushes for National Stem Cell Standards, OTCQB Uplist
https://allcapresearch.com/penny-stocks/f/adia-med-pushes-for-national-stem-cell-standards-otcqb-uplist?blogcategory=Pennystocks

$ADIA #StemCellTherapy

[i_like_bb_stock]

yea dont think we have much longer to wait

[downdraft]

Such a phenomenal CEO we have here! It will be difficult not to succeed with him running the show. Plus, a rapidly growing sales team must be smelling big money!

[i_like_bb_stock]

yes some big catalysts upcoming to break us over 10

[AyaStocks]

$ADIA as per usual the CEO does a great job of keeping us in the loop!

$ADIA

A quick update! pic.twitter.com/GD61LmlGFa

— Adia Nutrition (@ADIA_Nutrition) March 21, 2025

[Jaguarjacket]

About to go Ballistic ADIA Going OTCQB!

[Jaguarjacket]

Locked in and Loaded Up! ADIAs Time Has Come! True Valuation Correction UP! About to heat up. Let's Goooo!

[i_like_bb_stock]

audit almost done! OTCQB coming soon

$ADIA

A quick update! pic.twitter.com/GD61LmlGFa

— Adia Nutrition (@ADIA_Nutrition) March 21, 2025

[i_like_bb_stock]

agreed

[Jaguarjacket]

Extremely Bullish! ADIA!!!

[Jaguarjacket]

Uplisting to OTCQB, removal of 25 million shares, opening clinics nationwide, sales of branded stem cells with FDA approval! All coming together! I'm all in!!!$$$$

[Jaguarjacket]

Also, when more clinics open, and sales of signed stem cell contracts. It's coming, buckle up!

[AyaStocks]

Adia Med Leads Charge to Standardize Umbilical Cord Stem Cell Use Nationwide, Prepares Presentation for New Head of DHHS and FDA
March 20, 2025 9:30 AM EDT | Source: Adia Nutrition Inc.
Winter Park, Florida--(Newsfile Corp. - March 20, 2025) - Adia Med, a division of ADIA Nutrition Inc. (OTC Pink: ADIA), is driving a transformative effort to standardize umbilical cord stem cell use across the United States, prioritizing quality, safety, and accountability. This initiative sets rigorous best practices, mandates third-party verification, and ensures homologous applications, aiming to redefine excellence in regenerative medicine. Adia Med plans to present these pioneering standards to the new head of the Department of Health and Human Services, and the FDA, advocating for federal alignment to address widespread inconsistencies in stem cell therapies.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/10520/243473_fda.jpg

Cannot view this image? Visit:
https://images.newsfilecorp.com/files/10520/243473_fda.jpg

Patients nationwide have long grappled with a troubling issue: many clinics provide low-quality or non-viable—"dead"—stem cells, with no way for recipients to verify potency or quantity. This lack of oversight has eroded trust and limited the promise of regenerative medicine. Adia Med is stepping up to ensure every patient receives live, viable stem cells in the amounts promised, backed by unmatched quality controls.

"Umbilical cord stem cells could revolutionize healthcare, but only if patients can trust what they're getting," said Larry Powalisz, CEO of Adia Nutrition. "We're crafting a movement for reliability and excellence, and we're taking it to the new head of the Department of Health and Human Services and the FDA to create a national standard that protects patients and lifts the entire industry."

A Robust Standardization Framework
Adia Med's initiative rests on key pillars to fix current shortcomings:
Homologous Use Standards: Guidelines will ensure stem cells are used in line with their natural functions, boosting safety and effectiveness while curbing misuse risks.
Quality Control Protocols: Strict processes for harvesting, processing, and storing stem cells will maintain their therapeutic power, with standards covering donor screening, isolation, and banking.
Third-Party Verification: Every lab nationwide offering stem cell products would be required to provide third-party verification to guarantee a minimum stem cell count and viability for each batch, ensuring a consistent standard of quality, transparency, and reliability across the industry. This auditing ensures transparency and accountability.
Best Practices Development: Collaboration with stem cell experts, ethicists, and practitioners will produce adoptable standards to eliminate variability and enhance patient outcomes.

"Doctors should be getting their stem cells from a lab who has a third-party verified, FDA-validated process which guarantees quality, and we're pushing to make that the industry baseline with umbilical cord stem cells."

"Patients should never have to doubt the viability of their stem cells," said Dr. Sher, Chief Medical Officer of Stem Cells at Adia Med. "We're creating a standard where every patient receiving umbilical cord stem cells will receive a certificate from a third party, unequivocally verifying the quantity and viability of their specific batch." This hands-on assurance ensures doctors deliver stem cells from labs with independently verified, FDA-validated processes, setting a new benchmark for quality and boosting patient outcomes across the industry.

Tackling a Pressing Problem
Reports of patients receiving substandard or dead stem cells are rising, often unbeknownst to them. Adia Med's standards, backed by independent verification, will mandate live, viable cells in guaranteed minimum quantities, promising:
Patient Safety: Reduced risks from poor-quality cells or improper use.
Treatment Consistency: Reliable results nationwide, regardless of provider.
Industry Credibility: Ethical standards to eliminate bad actors and restore trust.

Federal Collaboration and Beyond
Adia Med aims to partner with the new head of the Department of Health and Human Services and the FDA, presenting these standards to shape a national framework. "With their leadership, we can end the uncertainty and deliver real benefits," Powalisz added. The company also invites input from regulators, medical professionals, and patient advocates, with participation details forthcoming at www.adiamed.com. Adia invites interested parties to reach out by filling out the contact form at www.adiamed.com.

For inquiries, questions, or further information, you can contact Larry Powalisz at ceo @101Dahlias-0850.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.

https://www.newsfilecorp.com/release/243473/Adia-Med-Leads-Charge-to-Standardize-Umbilical-Cord-Stem-Cell-Use-Nationwide-Prepares-Presentation-for-New-Head-of-DHHS-and-FDA

$ADIA

[i_like_bb_stock]

yep 2 things will move this and break us over 2, otcqb uplist and the 25M OS reduction

[downdraft]

Still very bullish here. Q2 should be our breakout quarter, mere weeks away. Just waiting patiently.

[BCNstocks]

Nice update. Stem cell therapy has the potential to revolutionize medicine—but only if it’s safe, standardized, and reliable. Adia Med’s new protocols will set homologous use standards, quality controls, and third-party verification to ensure every patient gets the best treatment possible.

Adia Med Leads Charge to Standardize Umbilical Cord Stem Cell Use Nationwide, Prepares Presentation for New Head of DHHS and FDA
https://www.newsfilecorp.com/release/243473/Adia-Med-Leads-Charge-to-Standardize-Umbilical-Cord-Stem-Cell-Use-Nationwide-Prepares-Presentation-for-New-Head-of-DHHS-and-FDA

[i_like_bb_stock]

news https://www.otcmarkets.com/stock/ADIA/news/Adia-Med-Leads-Charge-to-Standardize-Umbilical-Cord-Stem-Cell-Use-Nationwide-Prepares-Presentation-for-New-Head-of-DHHS-?id=471097